Schultz Christiane, Pecora Liberman Patricia Helena, Schmidt Goffi-Gomez Maria Valéria
Department of Audiology, AC Camargo Cancer Center, São Paulo, Brazil,
Department of Audiology, AC Camargo Cancer Center, São Paulo, Brazil.
Audiol Neurootol. 2019;24(5):253-257. doi: 10.1159/000502250. Epub 2019 Oct 29.
The most common complaint of patients affected by chemotherapy-induced hearing loss is difficulty understanding speech in noisy environments despite the use of hearing aids. Cochlear dead regions, those areas with damaged or absent inner hair cells and dendrites, may account for this type of hearing loss. However, it is unknown whether this condition is associated with cisplatin agents.
The aim of this study was to determine whether cisplatin is associated with hearing loss and cochlear dead regions.
This prospective cross-sectional study was conducted in patients participating in routine audiological monitoring during and after chemotherapy treatment. Adults undergoing audiological evaluation who had completed chemotherapy treatment were invited to participate. Patients were divided into 3 groups according to pure tone thresholds. Group 1 patients had thresholds over 70 dB (HL) at 2,000 Hz and higher frequencies. Group 2 patients had thresholds below 70 dB (HL) up to 2,000 Hz. Patients in the control group had normal thresholds at all frequencies. The threshold equalizing noise test (TEN[HL]) was used to identify cochlear dead regions by repeating thresholds in the presence of TEN noise played from a compact disc. The presence of cochlear dead regions was established when the masked threshold was 10 dB or greater above the TEN level and 10 dB or greater above the absolute threshold at any frequency.
Twelve patients were included in study group 1, 10 patients in study group 2, and 7 patients in the control group. Cochlear dead regions were present in all patients with hearing loss and in none of the control group. For groups 1 and 2, mean differences between absolute and masked thresholds were 21 and 16 dB at 500 Hz; 22 and 15 dB at 1,000 Hz; 31 and 17 dB at 2,000 Hz; 32 and 20 dB at 3,000 Hz; and 31 and 21 dB at 4,000 Hz, respectively. Nevertheless, analysis of variance testing with Bonferroni analysis showed a difference between groups 1 and 2 only at 2,000, 3,000, and 4,000 Hz.
We found unresponsive or dead cochlear regions in patients who had undergone cisplatin chemotherapy even among patients with mild to moderate hearing loss.
化疗所致听力损失患者最常见的主诉是即便使用了助听器,在嘈杂环境中理解言语仍有困难。耳蜗死区,即那些内毛细胞和树突受损或缺失的区域,可能是导致这类听力损失的原因。然而,这种情况是否与顺铂类药物有关尚不清楚。
本研究旨在确定顺铂是否与听力损失及耳蜗死区有关。
这项前瞻性横断面研究纳入了在化疗期间及化疗后接受常规听力学监测的患者。邀请完成化疗且正在接受听力学评估的成年人参与。根据纯音听阈将患者分为3组。第1组患者在2000Hz及更高频率时听阈超过70dB(HL)。第2组患者在2000Hz以下听阈低于70dB(HL)。对照组患者所有频率听阈均正常。通过在播放自光盘的阈上噪声(TEN)存在的情况下重复听阈,使用阈上噪声测试(TEN[HL])来识别耳蜗死区。当在任何频率下,掩蔽听阈比TEN水平高10dB或更多且比绝对听阈高10dB或更多时,确定存在耳蜗死区。
第1研究组纳入12例患者,第2研究组纳入10例患者,对照组纳入7例患者。所有听力损失患者均存在耳蜗死区,而对照组无一例出现。对于第1组和第2组,在500Hz时绝对听阈与掩蔽听阈的平均差值分别为21dB和16dB;在1000Hz时为22dB和15dB;在2000Hz时为31dB和17dB;在3000Hz时为32dB和20dB;在4000Hz时为31dB和21dB。然而,采用Bonferroni分析的方差分析显示,仅在2000Hz、3000Hz和4000Hz时第1组和第2组之间存在差异。
我们发现,即使在轻度至中度听力损失的患者中,接受顺铂化疗的患者也存在无反应或死亡的耳蜗区域。